BioCentury
ARTICLE | Clinical News

Selinexor: Phase II data

August 17, 2015 7:00 AM UTC

Karyopharm said that in July it amended the open-label, international Phase II SOPRA trial in patients ages >=60 with relapsed or refractory AML who are ineligible for intensive chemotherapy or transp...